MEI Pharma has dosed the first patient in a Phase II clinical trial of pracinostat, the company’s investigational oral histone deacetylase (HDAC) inhibitor, in patients with myelodysplastic syndrome (MDS) who either failed to respond or maintain a response to a hypomethylating agent (HMA) alone. The primary objective in the trial is to determine if the addition of pracinostat to Vidaza or Dacogen can improve clinical responses or rescue previous responses achieved with a HMA alone. This t...